Stocks › CHE
CHEMED CORP
CHE·NYSE·
United States·USD
$548.59
-2.74 (-0.50%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
CHE
CHEMED CORP · NYSE
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
CHES&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of CHE by members of U.S. Congress · 15 on record
Whale Activity
Position changes in CHE reported for 2026-09-30 by 591 institutional filers
- Increased144
- New71
- Held83
- Decreased226
- Closed44
- No prior filing23
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 1.5M | $733.6M | decreased |
| AQR CAPITAL MANAGEMENT LLC | 859.7K | $434.2M | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 855.5K | $432.1M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 586.6K | $296.3M | decreased |
| ACADIAN ASSET MANAGEMENT LLC | 461.7K | $233.2M | increased |
| STATE STREET CORP | 439.1K | $221.8M | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 402.1K | $203.1M | decreased |
| JPMORGAN CHASE & CO | 386.3K | $198.2M | decreased |
| Boston Partners | 377.0K | $190.4M | increased |
| DIMENSIONAL FUND ADVISORS LP | 271.3K | $137.0M | increased |
| MORGAN STANLEY | 255.8K | $129.2M | increased |
| Epoch Investment Partners, Inc. | 247.0K | $124.8M | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by CHE insiders, by quarter · Form 4
Recent Insider Transactions
1,668 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| LEE SPENCER Sexecutive vice president | Sale | −1,000 | $547.61 | $548K | Nov 11, 2026 | Form 4 ↗ |
| MCNAMARA KEVIN Jpresident and CEO · Director | Sale | −2,000 | $537.90 | $1.1M | Nov 3, 2026 | Form 4 ↗ |
| LEE SPENCER Sexecutive vice president | Sale | −920 | $537.17 | $494K | Nov 2, 2026 | Form 4 ↗ |
| MCNAMARA KEVIN Jpresident and CEO · Director | Sale | −2,000 | $513.45 | $1.0M | Sep 28, 2026 | Form 4 ↗ |
| HUTTON THOMAS Cvice president · Director | Tax withholding | −4,270 | $506.65 | $2.2M | Sep 28, 2026 | Form 4 ↗ |
| HUTTON THOMAS Cvice president · Director | Option exercise | +4,629 | $445.35 | $2.1M | Sep 28, 2026 | Form 4 ↗ |
| MCNAMARA KEVIN Jpresident and CEO · Director | Sale | −2,000 | $501.40 | $1.0M | Sep 18, 2026 | Form 4 ↗ |
| LEE SPENCER Sexecutive vice president | Sale | −1,000 | $541.04 | $541K | Aug 21, 2026 | Form 4 ↗ |
| MCNAMARA KEVIN Jpresident and CEO · Director | Sale | −2,000 | $541.16 | $1.1M | Aug 21, 2026 | Form 4 ↗ |
| Judkins Brian CVP and Chief Legal Officer | Tax withholding | −5,878 | $548.96 | $3.2M | Aug 10, 2026 | Form 4 ↗ |
| Judkins Brian CVP and Chief Legal Officer | Option exercise | +6,786 | $445.35 | $3.0M | Aug 10, 2026 | Form 4 ↗ |
| Wherley Joel LCEO - Vitas Healthcare | Tax withholding | −2,270 | $542.62 | $1.2M | Aug 5, 2026 | Form 4 ↗ |
| Wherley Joel LCEO - Vitas Healthcare | Option exercise | +2,599 | $445.35 | $1.2M | Aug 5, 2026 | Form 4 ↗ |
| MCNAMARA KEVIN Jpresident and CEO · Director | Sale | −2,000 | $539.51 | $1.1M | Aug 3, 2026 | Form 4 ↗ |
| MCNAMARA KEVIN Jpresident and CEO · Director | Tax withholding | −19.8K | $529.22 | $10.5M | Jul 31, 2026 | Form 4 ↗ |
| MCNAMARA KEVIN Jpresident and CEO · Director | Option exercise | +2,001 | $445.35 | $891K | Jul 31, 2026 | Form 4 ↗ |
| GRACE PATRICK PDirector | Sale | −190 | $532.00 | $101K | Jul 31, 2026 | Form 4 ↗ |
| LINDELL ANDREA RDirector | Sale | −1,347 | $447.33 | $603K | Jun 9, 2026 | Form 4 ↗ |
| WALSH GEORGE J IIIDirector | Sale | −500 | $437.83 | $219K | May 29, 2026 | Form 4 ↗ |
| WALSH GEORGE J IIIDirector | Grant / award | +386 | $440.77 | $170K | May 18, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding CHE · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF iShares Trust | 454.4K | $211.7M | 0.17% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 426.0K | $198.4M | 0.01% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 307.7K | $143.3M | 0.08% | Jun 30, 2026 |
| FULLERTHALER BEHAVIORAL SMALL CAP EQUITY Capitol Series Trust | 210.6K | $98.1M | 0.77% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 177.0K | $82.4M | 0.18% | Jun 30, 2026 |
| Disciplined Value Mid Cap Fund John Hancock Funds III | 176.1K | $82.0M | 0.35% | Jun 30, 2026 |
| First Trust SMID Cap Rising Dividend Achievers ETF First Trust Exchange-Traded Fund VI | 158.3K | $73.7M | 0.65% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 152.2K | $70.9M | 0.07% | Jun 30, 2026 |
| JPMorgan Mid Cap Value Fund J.P. Morgan Fleming Mutual Fund Group, Inc. | 151.2K | $70.4M | 0.63% | Jun 30, 2026 |
| Invesco S&P MidCap Quality ETF Invesco Exchange-Traded Fund Trust | 110.4K | $58.8M | 1.08% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list CHE's shares (CUSIP 16359R103), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming chemed as client
- HART HEALTH STRATEGIESCHEMED CORPORATION · 2024 Q3 · HCR$7K
Filing ↗ - HART HEALTH STRATEGIESCHEMED CORPORATION · 2024 Q2 · HCR$7K
Filing ↗ - HART HEALTH STRATEGIESCHEMED CORPORATION · 2024 Q1 · HCR$7K
Filing ↗ - HART HEALTH STRATEGIESCHEMED CORPORATION · 2023 Q4 · HCR$7K
Filing ↗ - HART HEALTH STRATEGIESCHEMED CORPORATION · 2023 Q3 · HCR$7K
Filing ↗
Government Contracts
Federal awards to CHEMED CORP · USAspending
No federal contract awards found for CHEMED CORP.
U.S. Patents
Recent USPTO applications naming CHEMED CORP
No USPTO patent applications found for CHEMED CORP.
Annual Financials
From CHE's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.53B | $2.43B | $2.26B | $2.13B | $2.14B |
| Operating income | $338.2M | $366.5M | $340.6M | $343.5M | $343.0M |
| Net income | $265.2M | $302.0M | $272.5M | $249.6M | $268.6M |
| Diluted EPS | $18.34 | $19.89 | $17.93 | $16.53 | $16.85 |
| Operating cash flow | $388.3M | $417.5M | $330.3M | $309.9M | $308.6M |
| Cash and equivalents | $74.5M | $178.3M | $264.0M | $74.1M | $32.9M |
| Total assets | $1.54B | $1.67B | $1.67B | $1.44B | $1.34B |
| Total liabilities | $558.8M | $549.6M | $560.2M | $643.3M | $719.5M |
| Shareholders' equity | $979.4M | $1.12B | $1.11B | $798.7M | $623.3M |
As CHEMED CORP tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 27, 2026 ↗
Stock Splits
Every split and reverse split in the price history
- 2-for-1Stock splitMay 12, 2005
- 2-for-1Stock splitNov 12, 1981
Split dates and ratios from the price history · Close Prices from Tiingo.com
About CHEMED CORP
From SEC EDGAR company records
Industry (SIC 8082)Services-Home Health Care Services
SectorHealthcare
HeadquartersCINCINNATI, OH
IncorporatedDE
SEC CIK0000019584 ↗
Former namesROTO-ROOTER INC








